Community-based mass treatment with azithromycin for the elimination of yaws in Ghana—Results of a pilot study by Abdul Aziz Abdulai (4288360)

“…We aimed to determine the efficacy of a single round of TCT with azithromycin to achieve a decrease in yaws prevalence in communities that are endemic for yaws and surrounded by other yaws-endemic areas.…”

Statins Have No Additional Benefit for Pulmonary Hypertension: A Meta-Analysis of Randomized Controlled Trials by Lin Wang (11986)

“…The results of our analysis showed that the statins can’t significantly increase 6-minute walking distance (6MWD, mean difference [MD] = -0.33 [CI: -18.25 to 17.59]), decrease the BORG dyspnea score (MD = -0.72 [CI: -2.28 to 0.85]), the clinical worsening risk (11% in statins vs. 10.1% in controls, Risk ratio = 1.06 [CI: 0.61, 1.83]), or the systolic pulmonary arterial pressure (SPAP) (MD = -0.72 [CI: -2.28 to 0.85]). …”

Conflicting selection pressures prevent the outgrowth of TIP-resistant HIV mutants in a host population. by Luke I. Rast (2735782)

“…For example, at <i>P</i> = 2.5, decreasing <i>η</i> results in major increases in transmission from TIP⁺ individuals (<a href="http://www.ploscompbiol.org/article/info:doi/10.1371/journal.pcbi.1004799#pcbi.1004799.g001" target="_blank">Fig 1B</a>) that overwhelm the modest decreases in transmission from TIP^- individuals, essentially removing the evolutionary conflict at the population-scale. …”

Supplementary Material for: Egr-1 Maintains NSC Proliferation and Its Overexpression Counteracts Cell Cycle Exit Triggered by the Withdrawal of Epidermal Growth Factor by Cera A.A. (5483699)

E4orf4 sensitizes cells to killing by drugs inducing DNA damage or replication stress. by Anna Brestovitsky (849835)

“…Cell survival was measured by a clonogenic assay using various cell dilutions, without further Dox addition. …”

Patient recruitment diagram. by Linda Ashman Kröönström (15243574)

“…</p><p>Results</p><p>There was a reported decrease in mobility from admission to discharge in both men (p = 0.02) and women (p = 0.01). …”

Protein expression of HO-1, HO-2 and Nrf2 in the gastric mucosa of intact rats and in those exposed to 75% ethanol with or without the pretreatment with CORM-2 applied i.g. in thre... by Katarzyna Magierowska (812683)

“…Panels A and C: pretreatment with CORM-2 (100 mg/kg i.g.) significantly decreased the signal of HO-1 (A) and Nrf2 (C) expression as compared to those recorded in vehicle-control gastric mucosa (p<0.05) as marked by cross. …”

Glass transition temperature of the dried spinning solution (1.8 M trehalose, 10 mM KCl, 5 mM glucose, 20 mM HEPES, 120 mM choline chloride, pH 7.4) using FTIR technique. by Nilay Chakraborty (343475)

Negative Epistasis between Sickle and Foetal Haemoglobin Suggests a Reduction in Protection against Malaria by Bruno P. Mmbando (737804)

“…An increase in HbF was associated with a decrease in risk of malaria OR=0.50 (95%CI: 0.28, 0.90; p=0.021) in HbAA, whereas for HbSS the risk of malaria increased OR=2.94 (1.44, 5.98; p=0.003). …”

Isolated coronary arteriole vasoreactivity. by Natia Q. Kelm (5683982)

Patient Preferences for Receiving Education on Venous Thromboembolism Prevention – A Survey of Stakeholder Organizations by Victor O. Popoola (2587510)

Older adults’ experiences of team-based home rehabilitation – a qualitative scoping review by Anette Johansson (21251989)

Data_Sheet_1_Are Reduced Levels of Coagulation Proteins Upon Admission Linked to COVID-19 Severity and Mortality?.PDF by Francisco C. Ceballos (8065037)

Depth-temperature profile for Shark 33 demonstrating a shift in vertical movement pattern. by John P. Tyminski (448811)

“…<p>The reverse diel vertical migration transitions with a progressive decrease in daytime surface time and increase in vertical oscillations forming V-shaped profiles that span both day and night.…”

Adverse event list. by Stefan Halbherr (21353882)

“…</p><p>Non-motor symptoms of PD, motor parkinsonian signs off medication, and quality of life improved significantly during the treatment phase, including the MDS-UPDRS total score (mean decrease −11.09; 95% Confidence Interval [CI]; −18, −4.1; <i>p</i> = 0.006), the Parkinson’s disease Questionnaire-39 (PDQ-39) summary index (mean decrease −2.91; 95% CI; −4.4, −1.4; <i>p</i> = 0.005), and the Non-Motor Symptoms Questionnaire (NMS-Quest) (mean decrease −4.27; 95% CI; −6.5, −2.1; <i>p</i> = 0.009). …”

Patient characteristics. by Stefan Halbherr (21353882)

“…</p><p>Non-motor symptoms of PD, motor parkinsonian signs off medication, and quality of life improved significantly during the treatment phase, including the MDS-UPDRS total score (mean decrease −11.09; 95% Confidence Interval [CI]; −18, −4.1; <i>p</i> = 0.006), the Parkinson’s disease Questionnaire-39 (PDQ-39) summary index (mean decrease −2.91; 95% CI; −4.4, −1.4; <i>p</i> = 0.005), and the Non-Motor Symptoms Questionnaire (NMS-Quest) (mean decrease −4.27; 95% CI; −6.5, −2.1; <i>p</i> = 0.009). …”

Supplementary Material for: Two Decades of Stroke in the United States: A Healthcare Economic Perspective by Lorio A. (17832122)

Socket Shield Technique to Improve the Outcomes of Immediate Implant: A Systematic Review and Meta-Analysis by Scarano, Antonio

“…Additionally, SST had a significant increase in implant stability (MD = 3.46, 95 % CI [1.22, 5.69], p = 0.002) and pink esthetic score (MD = 1.60, 95% CI [0.90, 2.30], p < 0.0001). …”
Get full text
Get full text

Mucosal-Associated Invariant T Cell Is a Potential Marker to Distinguish Fibromyalgia Syndrome from Arthritis by Chie Sugimoto (245505)

“…</p><p>Results</p><p>There was a decrease in the MAIT cell population in FMS, RA, and SpA compared with HD. …”

Cholesteryl Ester Transfer Protein Inhibitors in the Treatment of Dyslipidemia: A Systematic Review and Meta-Analysis by Chuanwei Li (477417)

“…Our meta-analysis revealed that CETP inhibitors increased the HDL-c levels (n = 2826, p<0.00001, mean difference (MD)  = 20.47, 95% CI [19.80 to 21.15]) and total cholesterol (n = 3423, p = 0.0002, MD = 3.57, 95%CI [1.69 to 5.44] to some extent combined with a reduction in triglyceride (n = 3739, p<0.00001, MD = −10.47, 95% CI [−11.91 to −9.03]) and LDL-c (n = 3159, p<0.00001, MD = −17.12, 95% CI [−18.87 to −15.36]) irrespective of mono-therapy or co-administration with statins. …”